羟基脲胶囊HYDREA(hydroxyurea)说明书

药店国别：无 产地国家：美国 处方药：是 所属类别： 500毫克/胶囊 100胶囊/瓶 包装规格： 500毫克/胶囊 100胶囊/瓶 计价单位：瓶 生产厂家中文参考译名：无 生产厂家英文名：BRISTOL MYERS SQUIBB 原产地英文商品名：HYDREA 500mg/Capsule 100Capsules/bottle 原产地英文药品名：HYDROXYUREA 中文参考商品译名：HYDREA 500毫克/胶囊 100胶囊/ 中文参考药品译名：羟基脲 曾用名：无

简介

部份中文羟基脲处方资料（仅供参考） 药品英文名：Hydroxycarbamide 药品别名：氨基甲酰基羟胺、氨基酰羟基胺、氨甲酰基胺、羟基脲素、羟脲、HU、Hydrea、Hydroxicarbamidum、Hydroxycarbamidum、Hydroxyurea、Hydura、Idroxicarbamide 药物剂型 1.片剂：500mg； 2.胶囊：400mg。 药理作用 为核苷酸还原酶抑制剂，对多种实验肿瘤有抑制作用。能抑制核糖核酸还原为脱氧核糖核酸，选择性抑制DNA合成，对RNA及蛋白质无阻断作用。 本品为细胞周期特异性药物，选择性杀伤S期细胞，并能使癌细胞集中于G1期达到同步化，而G1期细胞对放射线高度敏感，故与放疗合并应用可能起增敏作用。 药动学 口服易吸收，tmax为1h，然后迅速下降。血浆半衰期约2h。1次给药在24h内排出50%～80%。 本品能通过血-脑脊液屏障，易透过红细胞膜。 适应证 1.主要用于治疗慢性髓细胞白血病、黑色素瘤、真性红细胞增多症、多发性骨髓瘤。 2.对头颈部原发性鳞状细胞癌、复发性转移性卵巢癌、肾细胞癌等亦有一定的疗效。与放射治疗同时应用或作为放射的增敏剂，可增加治疗头颈部肿瘤的疗效。 禁忌证 1.水痘、带状疱疹患者及各种严重感染者。 2.儿童、孕妇、哺乳妇女禁用。 注意事项 1.有以下疾病慎用：(1)严重贫血者；(2)骨髓抑制者；(3)肾功能不全者；(4)有痛风、尿酸盐结石史者。 2.服用本药6周仍未见效，应考虑停药。 不良反应 1.造血系统：较常见的有白细胞减少、贫血或红细胞形态异常，少见的有血小板减少。白细胞减少通常在治疗开始后约10天发生，少数可合并感染；红细胞可出现巨幼红样变，形态类似恶性贫血，但其发生与维生素B12或叶酸缺乏无关。 2.消化系统：较常见的有食欲减退、恶心、呕吐，少见的有便秘，一般用药后6～12h可出现。长期服用本药可发生口腔黏膜炎、口腔溃疡等。 3.神经系统：偶见头痛、头晕、嗜睡、幻觉、惊厥等表现。4.其他：皮疹、红斑、瘙痒等皮肤反应较少见。 用法用量 1.成人： (1)口服给药： ①慢性粒细胞白血病：可根据患者病情及白细胞计数而决定用药剂量，一般开始剂量为每天20～30mg/kg，一次服用或分2次服用。当起效后，白细胞计数降至10×109/L以下时，应减量至每天20mg/kg维持治疗。 ②头颈癌：剂量为每次60～80mg/kg或2000～3000mg/m2，每3天口服一次，单独服用或与放疗合用。亦可每天20～30mg/kg，每天1次。 ③卵巢癌：同头颈癌。 ④真性红细胞增多症、原发性血小板增多症，用法为：一天30～40mg/kg，每天1次或分2次服用。待红细胞或血小板降至正常高限时改用维持量，即10～20mg/kg，每天1次。 ⑤急性白血病伴高白细胞血症，有用法为：每次50～70mg/kg，每天1次，通常用2～3天，当白细胞明显成倍下降时，应尽早开始联合化疗。 2.儿童：尚不明确。 药物相应作用 1.与可使白细胞或血小板减少的药物合用时，应严密观察患者的血象，并根据白细胞及血小板计数适当调整羟基脲的用量。 2.由于服用本药后会使患者的免疫功能受到抑制，也可减弱患者接种疫苗后产生抗体的反应，最好停用本药3个月到1年才接种疫苗。 与活疫苗(如轮状病毒疫苗)合用，将增加活疫苗感染的风险。接受免疫抑制化疗的患者不能接种活疫苗。缓解期白血病患者，至少要停止化疗3个月，才允许接种活疫苗。

英文版说明

HYDROXYUREA CAPSULES, USPRx onlyDescriptionHydroxyurea Capsules, USP is an antineoplastic agent, occurs as an essentially tasteless, white crystalline powder. Its structural formula is:CH4N2O2 Molecular Weight: 76.06 Each capsule, for oral administration contains 500 mg hydroxyurea. In addition, each capsule contains the following inactive ingredients: citric acid, dibasic sodium phosphate, lactose monohydrate, and magnesium stearate.The capsule shell contains: Benzyl alcohol, butyl paraben, D & C red no. 28, edetate calcium disodium, FD & C blue no. 1, FD & C red no. 40, gelatin, iron oxide red, methyl paraben, propyl paraben, sodium lauryl sulfate, sodium propionate, and titanium dioxide.The imprinting ink contains D & C yellow no. 10 aluminum lake, FD & C blue no. 1 aluminum lake, FD & C blue no. 2 aluminum lake, FD & C red no. 40 aluminum lake, pharmaceutical glaze, propylene glycol and synthetic black iron oxide.Clinical PharmacologyMechanism of ActionThe precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects.Three mechanisms of action have been postulated for the increased effectiveness of concomitant use of hydroxyurea therapy with irradiation on squamous cell (epidermoid) carcinomas of the head and neck. In vitro studies utilizing Chinese hamster cells suggest that hydroxyurea (1) is lethal to normally radioresistant S-stage cells, and (2) holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of in vitro studies of HeLa cells: it appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; RNA and protein syntheses have shown no alteration.PharmacokineticsSpecial PopulationsAnimal Pharmacology and ToxicologyThe oral LD50 of hydroxyurea is 7330 mg/kg in mice and 5780 mg/kg in rats, given as a single dose.In subacute and chronic toxicity studies in the rat, the most consistent pathological findings were an apparent dose-related mild to moderate bone marrow hypoplasia as well as pulmonary congestion and mottling of the lungs. At the highest dosage levels (1260 mg/kg/day for 37 days then 2520 mg/kg/day for 40 days), testicular atrophy with absence of spermatogenesis occurred; in several animals, hepatic cell damage with fatty metamorphosis was noted. In the dog, mild to marked bone marrow depression was a consistent finding except at the lower dosage levels. Additionally, at the higher dose levels (140 to 420 mg or 140 to 1260 mg/kg/week given 3 or 7 days weekly for 12 weeks), growth retardation, slightly increased blood glucose values, and hemosiderosis of the liver or spleen were found; reversible spermatogenic arrest was noted. In the monkey, bone marrow depression, lymphoid atrophy of the spleen, and degenerative changes in the epithelium of the small and large intestines were found. At the higher, often lethal, doses (400 to 800 mg/kg/day for 7 to 15 days), hemorrhage and congestion were found in the lungs, brain, and urinary tract. Cardiovascular effects (changes in heart rate, blood pressure, orthostatic hypotension, EKG changes) and hematological changes (slight hemolysis, slight methemoglobinemia) were observed in some species of laboratory animals at doses exceeding clinical levels.Indications and UsageSignificant tumor response to hydroxyurea capsules, USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary.Hydroxyurea used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.ContraindicationsHydroxyurea is contraindicated in patients with marked bone marrow depression, i.e., leukopenia (<2500 WBC) or thrombocytopenia (<100,000), or severe anemia.Hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation.WarningsTreatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed (see CONTRAINDICATIONS). Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often, and are seldom seen without a preceding leukopenia. However, the recovery from myelosuppression is rapid when therapy is interrupted. It should be borne in mind that bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; hydroxyurea should be used cautiously in such patients.Patients who have received irradiation therapy in the past may have an exacerbation of postirradiation erythema.Fatal and nonfatal pancreatitis have occurred in HIV-infected patients during therapy with hydroxyurea and didanosine, with or without stavudine. Hepatotoxicity and hepatic failure resulting in death have been reported during post-marketing surveillance in HIV infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine, with or without stavudine.Severe anemia must be corrected before initiating therapy with hydroxyurea.Erythrocytic abnormalities: megaloblastic erythropoiesis, which is self-limiting, is often seen early in the course of hydroxyurea therapy. The morphologic change resembles pernicious anemia, but is not related to vitamin B12 or folic acid deficiency. Hydroxyurea may also delay plasma iron clearance and reduce the rate of iron utilization by erythrocytes, but it does not appear to alter the red blood cell survival time.Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen (see PRECAUTIONS: Geriatric Use).In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or associated with the patient's underlying disease.Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxyurea should be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive agents should be initiated as indicated.Carcinogenesis and MutagenesisHydroxyurea is genotoxic in a wide range of test systems and is thus presumed to be a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patient's underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxyurea.Conventional long-term studies to eva luate the carcinogenic potential of hydroxyurea have not been performed. However, intraperitoneal administration of 125-250 mg/kg hydroxyurea (about 0.6-1.2 times the maximum recommended human oral daily dose on a mg/m2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic in vitro to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic in vitro (hamster cells, human lymphoblasts) and in vivo (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype.PregnancyDrugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents. The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception.Hydroxyurea capsules, USP can cause fetal harm when administered to a pregnant woman. Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs and monkeys at doses within 1-fold of the human dose given on a mg/m2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m2 basis) to rats caused growth retardation and impaired learning ability. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.PrecautionsTherapy with hydroxyurea requires close supervision. The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of the hemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxyurea therapy. If the white blood cell count decreases to less than 2500/mm3, or the platelet count to less than 100,000/mm3, therapy should be interrupted until the values rise significantly toward normal levels. Severe anemia, if it occurs, should be managed without interrupting hydroxyurea therapy.Hydroxyurea should be used with caution in patients with marked renal dysfunction. (See CLINICAL PHARMACOLOGY: Special Populations; DOSAGE AND ADMINISTRATION.)Hydroxyurea is not indicated for the treatment of HIV infection; however, if HIV-infected patients are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis and hepatotoxicity is recommended. Patients who develop signs and symptoms of pancreatitis or hepatotoxicity should permanently discontinue therapy with hydroxyurea. (See WARNINGS and ADVERSE REACTIONS.)Carcinogenesis, Mutagenesis, Impairment of FertilitySee WARNINGS for Carcinogenesis and Mutagenesis information.PregnancyPregnancy Category D. (See WARNINGS.)Nursing MothersHydroxyurea is excreted in human milk.Because of the potential for serious adverse reactions with hydroxyurea, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UseSafety and effectiveness in pediatric patients have not been established.Geriatric UseElderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen.This drug is known to be excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION: Renal Insufficiency).Drug InteractionsProspective studies on the potential for hydroxyurea to interact with other drugs have not been performed.Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events. (See WARNINGS and ADVERSE REACTIONS.)Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary.Information for PatientsHydroxyurea is a medication that must be handled with care. People who are not taking hydroxyurea should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling hydroxyurea or bottles containing hydroxyurea. Anyone handling hydroxyurea should wash their hands before and after contact with the bottle or capsules. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules.Adverse ReactionsAdverse reactions have been primarily bone marrow depression (leukopenia, anemia, and occasionally thrombocytopenia), and less frequently gastrointestinal symptoms (stomatitis, anorexia, nausea, vomiting, diarrhea, and constipation), and dermatological reactions such as maculopapular rash, skin ulceration, dermatomyositis-like skin changes, peripheral and facial erythema. Hyperpigmentation, atrophy of skin and nails, scaling and violet papules have been observed in some patients after several years of long-term daily maintenance therapy with hydroxyurea. Skin cancer has been reported. Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy (see WARNINGS). Dysuria and alopecia occur very rarely. Large doses may produce moderate drowsiness. Neurological disturbances have occurred extremely rarely and were limited to headache, dizziness, disorientation, hallucinations, and convulsions. Hydroxyurea capsules, USP occasionally may cause temporary impairment of renal tubular function accompanied by elevations in serum uric acid, BUN, and creatinine levels. Abnormal BSP retention has been reported. Fever, chills, malaise, edema, asthenia, and elevation of hepatic enzymes have also been reported.Adverse reactions observed with combined hydroxyurea and irradiation therapy are similar to those reported with the use of hydroxyurea or radiation treatment alone. These effects primarily include bone marrow depression (anemia and leukopenia), gastric irritation, and mucositis. Almost all patients receiving an adequate course of combined hydroxyurea and irradiation therapy will demonstrate concurrent leukopenia. Platelet depression (<100,000 cells/mm3) has occurred rarely and only in the presence of marked leukopenia. Hydroxyurea may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.The association of hydroxyurea with the development of acute pulmonary reactions consisting of diffuse pulmonary infiltrates, fever and dyspnea has been rarely reported. Pulmonary fibrosis also has been reported rarely.Fatal and nonfatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxyurea in combination with antiretroviral agents, in particular, didanosine plus stavudine. Patients treated with hydroxyurea in combination with didanosine, stavudine, and indinavir in Study ACTG 5025 showed a median decline in CD4 cells of approximately 100/mm3. (See WARNINGS and PRECAUTIONS.)OverdosageAcute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet erythema, edema on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and stomatitis have also been observed.Dosage and AdministrationTo minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing hydroxyurea capsules. This includes all handling activities in clinical settings, pharmacies, storerooms, and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration.Procedures for proper handling and disposal of antineoplastic drugs should be considered. Several guidelines on this subject have been published.1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.Because of the rarity of melanoma, resistant chronic myelocytic leukemia, carcinoma of the ovary, and carcinomas of the head and neck in pediatric patients, dosage regimens have not been established.All dosage should be based on the patient’s actual or ideal weight, whichever is less. Concurrent use of hydroxyurea with other myelosuppressive agents may require adjustment of dosages.Solid TumorsResistant Chronic Myelocytic LeukemiaUntil the intermittent therapy regimen has been eva luated, CONTINUOUS therapy (20 to 30 mg/kg administered orally as a single dose daily) is recommended.An adequate trial period for determining the antineoplastic effectiveness of hydroxyurea is six weeks of therapy. When there is regression in tumor size or arrest in tumor growth, therapy should be continued indefinitely. Therapy should be interrupted if the white blood cell count drops below 2500/mm3, or the platelet count below 100,000/mm3. In these cases, the counts should be reeva luated after three days, and therapy resumed when the counts return to acceptable levels. Since the hematopoietic rebound is prompt, it is usually necessary to omit only a few doses. If prompt rebound has not occurred during combined hydroxyurea capsules, USP and irradiation therapy, irradiation may also be interrupted. However, the need for postponement of irradiation has been rare; radiotherapy has usually been continued using the recommended dosage and technique. Severe anemia, if it occurs, should be corrected without interrupting hydroxyurea therapy. Because hematopoiesis may be compromised by extensive irradiation or by other antineoplastic agents, it is recommended that hydroxyurea be administered cautiously to patients who have recently received extensive radiation therapy or chemotherapy with other cytotoxic drugs.Pain or discomfort from inflammation of the mucous membranes at the irradiated site (mucositis) is usually controlled by measures such as topical anesthetics and orally administered analgesics. If the reaction is severe, hydroxyurea therapy may be temporarily interrupted; if it is extremely severe, irradiation dosage may, in addition, be temporarily postponed. However, it has rarely been necessary to terminate these therapies.Severe gastric distress, such as nausea, vomiting, and anorexia, resulting from combined therapy may usually be controlled by temporary interruption of hydroxyurea administration.Renal InsufficiencyAs renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage of hydroxyurea in patients with renal impairment. (See PRECAUTIONS and CLINICAL PHARMACOLOGY.) Close monitoring of hematologic parameters is advised in these patients.Hepatic InsufficiencyThere are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients.How SuppliedHydroxyurea Capsules, USP are available as:500 mg: Purple opaque cap and pink opaque body filled with white powder. Imprinted in black ink stylized barr 882. Available in bottles of:100 NDC 0555-0882-02Dispense with a child-resistant closure in a tight container.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]